H.C. Wainwright reiterates Neutral rating on CareDx stock By Investing.com

CareDx reported Q1 2026 revenue of $117.7 million, up 39% year over year and above expectations, with testing revenue rising 48% to $91.4 million and adjusted/non-GAAP net income reaching $18.1 million. Management raised full-year 2026 revenue guidance to $447 million-$465 million from $420 million-$444 million and expects adjusted EBITDA of $43 million-$57 million. H.C. Wainwright kept a Neutral rating, while BTIG lifted its price target to $28 from $26 and maintained a Buy rating.

Analysis

This is less a clean “beat and raise” than a transition from single-product leverage to a broader, more defensible platform. The key second-order effect is that the mix is improving while the company is simultaneously recycling a non-core asset sale into a higher-growth oncology adjacency, which should reduce dependence on kidney transplant testing over the next 12-18 months. That matters because the market typically pays up when a diagnostics company can show both volume growth and a path to a second engine, not just a one-quarter utilization pop.

The real debate is not whether growth is strong, but whether the forward revenue-per-test target is achievable without lowering quality of demand. If the step-up in revenue per test is driven by payer mix, contract normalization, and reduced out-of-period noise, margin durability is better than the headline suggests; if it is partially accounting timing, then near-term upside can flatten quickly in 2-3 quarters. Naveris also introduces integration and commercialization risk: oncology diagnostics often require more expensive physician education and slower reimbursement conversion, so the acquisition is strategically smart but likely dilutive to management bandwidth before it is accretive to EBITDA.

Consensus is probably underappreciating the balance-sheet optionality. A cash-funded tuck-in after a divestiture means the company can pivot growth without taking on leverage, which lowers downside in a risk-off tape and may warrant a rerating if execution holds through the next two quarters. The contrarian risk is that investors extrapolate guidance too aggressively into 2027 while ignoring that diagnostics multiples compress hard if growth decelerates from 20%+ to low teens once the post-deal transition normalizes.

Key Decisions for Investors

• Go long CDNA on pullbacks over the next 1-2 weeks, using the post-earnings base as the entry window; risk/reward favors upside continuation if management sustains guidance commentary and integration risk stays contained.
• For more convex exposure, buy CDNA call spreads 3-6 months out; the setup is attractive if the market starts pricing the Naveris acquisition as an additional growth leg rather than a one-time transaction.
• Pair trade: long CDNA / short a slower-growth diagnostics peer with less balance-sheet flexibility over the next 2-4 quarters; the goal is to isolate the rerating from capital allocation and multi-engine growth while reducing sector beta.
• If CDNA gaps sharply on optimism, trim into strength rather than chase; the stock likely trades best on execution milestones over the next two earnings prints, not on headline guidance alone.